R&D News | pharmaphorum

News

Study reignites debate on GLP-1 drugs and suicide risk

A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there w

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

News

Buoyed by muscular dystrophy data, Avidity raises $345m

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an imp

News

GSK bags breakthrough status for B7-H3 ADC for lung cancer

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA.

News

US govt taps Walgreens for decentralised trials

Retail pharmacy giant Walgreens has signed a five-year contract with the US government – worth up to $100 million – for access to its decentralised clinical trials (DCT) network.

Study reignites debate on GLP-1 drugs and suicide risk

Lilly says tirzepatide staves off diabetes in phase 3 trial

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Buoyed by muscular dystrophy data, Avidity raises $345m

GSK bags breakthrough status for B7-H3 ADC for lung cancer

US govt taps Walgreens for decentralised trials

ILiAD bags $115m for pertussis vaccine, and other financings

How to meet your physicians where they are online

News

Editor's Picks